Gross proceeds to the Company from the public providing and the private placement are anticipated to be approximately $5.5 million in the aggregate. Closing of the public offering is planned for February 10, 2015 at the mercy of customary closing conditions. THE BUSINESS intends to use the net proceeds from the general public offering for continued advancement of product applicants through medical trials and for working capital and general corporate purposes. MLV & Co. LLC can be acting as the Sole Book-Running Manager for the offering.. Asterias Biotherapeutics prices underwritten open public offering of common share at $3.90 per share Asterias Biotherapeutics, Inc.Ms Hayles, a previous physical education teacher, saw the impact modern day lifestyles possess on Australian kids and decided to do something positive about it. A brief five-week introductory Activation plan will be provided by Charles Darwin University Sport from 15 November to 17 December. Interested people can register their interest in the Activation Plan with Charles Darwin University Sport on 08 8946 6971.

Baxa launches ExactaMix 1200 Automated Compounding Device Baxa Corporation, a respected company of medical systems and products that automate pharmacy functions, today introduced the ExactaMix 1200 Automated Compounding Gadget for little – to mid-sized medical center pharmacies looking for an automated method of compounding large-volume parenteral dosages.